Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- FED Front & Center Again
- Roundtable Top Picks of the Week
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/19: Will Bernanke Clarify Matters Today?
- PFP 6/19: Investors Bold in Wake of the Fed
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| OLD SECOND B | OSBC | 4.22% |
| VANTIV INC | VNTV | 3.78% |
| SONIC FOUNDR | SOFO | 3.73% |
| SUMITOMO MIT | SMFG | 3.38% |
| NIPPON TELEG | NTT | 2.95% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We recently upgraded SurModics Inc. (SRDX - Analyst Report) to Outperform from Neutral following its impressive showing in the second quarter of fiscal 2012 (ended March 31, 2012). Our decision is justified by the Zacks #2 Rank (Buy rating) carried by the company in the short run.
SurModics’ second quarter fiscal 2012 adjusted earnings of $0.14 per share beat the Zacks Consensus Estimate by $0.02. The earnings beat was attributable to higher-than-expected revenues. Given SurModic’s strong product portfolio, we expect it to achieve the fiscal 2012 revenue guidance of $47-$51 million.
We are also pleased with the sale of SurModics’ Pharmaceuticals unit as this has allowed the company to focus on its core businesses. We note that performance of the company has been steadily improving since a disappointing fiscal 2010.
The company took a number of corrective measures, including a change at its helm. We believe SurModics will continue performing well going forward and have raised our earnings estimates for fiscal 2012 and fiscal 2013.
Following the disappointing performance in fiscal 2010, SurModics revamped its board of directors and appointed a new CEO, Gary R. Maharaj. We note that Maharaj is the former President and CEO of Arizant Inc., which was sold to 3M Co. (MMM - Analyst Report) in October 2010.
We are also impressed by SurModics’ strong financial position. At the end of the second quarter of fiscal 2012, the company had cash and investments totaling $102.6 million with no long-term debt burden. The amount is inclusive of $2.9 million (already released from escrow) pertaining to the sale of the Pharma unit. The company generated operating cash flow of $4.2 million in the second quarter of fiscal 2012, up 121% sequentially.
We believe the strong cash position augurs well for further acquisitions in addition to investment in the current business and share repurchases. A $50 million share buyback program was cleared by the Board of Directors in May 2012. We believe that the buyback program highlights the company’s commitment to create value for shareholders.
Get the full Analyst Report on MMM - FREE
Get the full Analyst Report on SRDX - FREE